The PD-1/PD-L1 blocking response is associated with numerous tumor-intrinsic and tumor immune microenvironment characteristics54,55; as a result, a considerable proportion of patients show no response or develop resistance to PD-1/PD-L1 blockade therapy. Here, CD274 is linked to neoplasm.